<DOC>
	<DOCNO>NCT02180061</DOCNO>
	<brief_summary>This study ass safety , tolerability , efficacy every-3-week dosing ( Q3W ) pembrolizumab ( MK-3475 ) participant advance melanoma ; participant may receive pembrolizumab 2 year derive clinical benefit . The primary study hypothesis treatment single agent pembrolizumab result clinically meaningful overall response rate .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Participants With Advanced Melanoma ( MK-3475-041/KEYNOTE-041 )</brief_title>
	<detailed_description>Participants discontinue pembrolizumab achieve complete response ( CR ) subsequently develop progressive disease ( PD ) may eligible enter Second Course Phase receive pembrolizumab . The end study participant occur : 1 ) marketing approval pembrolizumab melanoma , 2 ) completion safety follow 3 ) time possibility entry second course treatment lose , whichever occurs last .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm diagnosis locally advance ( unresectable Stage III ) metastatic ( Stage IV ) melanoma amenable local therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 At least one measurable lesion Adequate organ function Exclusion criterion : Prior therapy antiprogrammed cell death1 ( antiPD1 ) , antiPD ligand1 ( PDL1 ) , antiPDL2 , antiCD137 antibody , anticytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) agent Is currently participate participate study investigational compound device within 30 day , 5X halflife investigational compound , whichever longer , initial dosing study Chemotherapy , target small molecule therapy , radiotherapy , biological cancer therapy ( include monoclonal antibody ) within 4 week prior first dose trial treatment , recover ( &lt; = Grade 1 baseline ) adverse event due previously administer agent Expected require form systemic localize antineoplastic therapy study Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Documented history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent Receiving systemic steroid therapy form immunosuppressive therapy within 1 week prior first dose study treatment Received live vaccine within 4 week prior first dose trial treatment Has know hypersensitivity component study drug another monoclonal antibody History evidence active pneumonitis Human immunodeficiency virus ( HIV ) positive Has know history active Hepatitis B C Pregnant , breastfeeding , expect conceive father child within project duration trial treatment 120 day last dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>